Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
TV & Film
Sports
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/f1/b9/ab/f1b9abe2-cfe0-a121-a86e-a9e051e550b8/mza_3957851291692824620.png/600x600bb.jpg
The Fellow on Call: The Heme/Onc Podcast
Rouleaux University Medical Center
147 episodes
1 week ago
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
RSS
All content for The Fellow on Call: The Heme/Onc Podcast is the property of Rouleaux University Medical Center and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
Show more...
Medicine
Education,
How To,
Health & Fitness,
Science,
Life Sciences
https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1742927008537-7LUCMYET9YQIOT92OKZ7/Ep+131.jpg?format=1500w
Episode 131: VTE Series-Approach to workup and initial management
The Fellow on Call: The Heme/Onc Podcast
7 months ago
Episode 131: VTE Series-Approach to workup and initial management
This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success! Episode contents: -What is venous thromboembolism? - How do we diagnose patients with VTE? - How do we initially management patients with VTE? - How do we select anticoagulants for VTE? ****This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast
The Fellow on Call: The Heme/Onc Podcast
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast